4//SEC Filing
PATOU GARY 4
Accession 0000950170-24-130378
CIK 0001582313other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 7:48 PM ET
Size
16.4 KB
Accession
0000950170-24-130378
Insider Transaction Report
Form 4
PATOU GARY
Director
Transactions
- Tax Payment
Common Shares
2024-11-22$39.80/sh−649$25,830→ 26,424 total - Tax Payment
Common Shares
2024-11-22$39.80/sh−1,046$41,631→ 25,613 total - Exercise/Conversion
Common Shares
2024-11-22$7.38/sh+3,500$25,830→ 27,073 total - Exercise/Conversion
Common Shares
2024-11-22$13.48/sh+3,086$41,599→ 26,659 total - Sale
Common Shares
2024-11-22$41.11/sh−2,851$117,205→ 23,573 total - Sale
Common Shares
2024-11-22$41.05/sh−2,040$83,742→ 23,573 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-22−3,500→ 0 totalExercise: $7.38Exp: 2026-06-01→ Common Shares (3,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-22−3,086→ 0 totalExercise: $13.48Exp: 2025-05-03→ Common Shares (3,086 underlying)
Holdings
- 4,902(indirect: See Note)
Common Shares
Footnotes (3)
- [F1]Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations.
- [F2]By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
- [F3]The shares subject to the option are fully vested and exercisable.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001283535
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 7:48 PM ET
- Size
- 16.4 KB